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Abstract
Background: Many HIV-infected children in sub-Saharan Africa reside in rural areas, yet most research on treatment
outcomes has been conducted in urban centers. Rural clinics and residents may face unique barriers to care and treatment.
Methods: A prospective cohort study of HIV-infected children was conducted between September 2007 and September
2010 at the rural HIV clinic in Macha, Zambia. HIV-infected children younger than 16 years of age at study enrollment who
received antiretroviral therapy (ART) during the study were eligible. Treatment outcomes during the first two years of ART,
including mortality, immunologic status, and virologic suppression, were assessed and risk factors for mortality and virologic
suppression were evaluated.
Results: A total of 69 children entered the study receiving ART and 198 initiated ART after study enrollment. The cumulative
probabilities of death among children starting ART after study enrollment were 9.0% and 14.4% at 6 and 24 months after
ART initiation. Younger age, higher viral load, lower CD4+ T-cell percentage and lower weight-for-age z-scores at ART
initiation were associated with higher risk of mortality. The mean CD4
+ T-cell percentage increased from 16.3% at treatment
initiation to 29.3% and 35.0% at 6 and 24 months. The proportion of children with undetectable viral load increased to
88.5% and 77.8% at 6 and 24 months. Children with longer travel times ($5 hours) and those taking nevirapine at ART
initiation, as well as children who were non-adherent, were less likely to achieve virologic suppression after 6 months of
ART.
Conclusions: HIV-infected children receiving treatment in a rural clinic experienced sustained immunologic and virologic
improvements. Children with longer travel times were less likely to achieve virologic suppression, supporting the need for
decentralized models of ART delivery.
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Introduction
More than 90% of the 2 million children living with HIV
worldwide reside in sub-Saharan Africa [1]. With increasing
evidence that pediatric treatment programs in resource-poor
settings can achieve treatment outcomes comparable to those of
developed countries [2,3], most countries in sub-Saharan Africa
have implemented policies to increase access to antiretroviral
therapy (ART). However, considerable inequities in access to
treatment remain [4], as most HIV services are concentrated in
urban areas distant from where many HIV-infected children
reside.
Rural clinics and residents face unique barriers to care and
treatment.Shortages of health care personnel,equipment and drugs
may more heavily affect rural clinics, and several studies identified
limited modesoftransportationandfood securityasfactorsaffecting
the ability of rural residents to access care and treatment [5,6,7,8].
These factors may impact treatment responses of children. A recent
study comparing HIV-infected children receiving ART in urban
and rural Zambia found higher levels of undernutrition and
mortality throughout treatment in the rural clinics [9]. To minimize
barriers to care, different models of service delivery have been
implemented in rural areas to increase accessibility of ART,
including the use of nurses [10,11,12,13,14,15] and general
practitioners [16] in the provision of ART at primary care clinics,
and home-based care provided by trained field officers [17] and
volunteers [18]. Consequently, evaluation of treatment programs
and treatment outcomes in rural settings is needed. Several reports
are available from rural programs [10,12,13,14,15,16,17,18,19],
but few focus on children [5,11].
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19006This observational cohort study reports immunologic and
virologic treatment outcomes and mortality among HIV-infected
children receiving up to two years of treatment at a rural HIV
clinic in Macha, Zambia.
Materials and Methods
Ethics Statement
The study was approved by the Ministry of Health in Zambia, the
Research Ethics Committee of the University of Zambia and the
Institutional Review Board of the Johns Hopkins Bloomberg School of
Public Health. Written informed consent was obtained from parents or
guardians and assent was obtained from children 8–16 years of age.
Study setting and population
The study was conducted at Macha Hospital in rural Southern
Province, Zambia. The study setting has been described in detail
elsewhere [5]. Briefly, the catchment area of Macha Hospital is
populated primarily by traditional villagers living in small, scattered
homesteads. Macha Hospital is a 208-bed district-level referral
hospital administered by the Zambian Brethren in Christ Church
that functions within the healthcare system of the Ministry of
Health. Since 2005, Macha Hospital has been one of the primary
ART providers in the district and has cared for over 6000 HIV-
infected adults and children through the Government of Zambia’s
antiretroviral treatment program, with additional support from the
President’s Emergency Plan for AIDS Relief (PEPFAR) through the
non-governmental organization AidsRelief.
HIV-infected children are referred to the clinic from voluntary
counseling and testing programs, in- and outpatient clinics, and rural
health centers. Since February 2008, children born to HIV-infected
women are routinely tested for HIV infection at approximately 6 weeks
of age using dried blood spot samples transported to Lusaka, Zambia
for HIV DNA PCR. Clinical care is provided without charge by
medical doctors and clinical officers, and adherence counseling by
nurses and trained counselors. Eligibility for ART is determined based
on WHO treatment guidelines [20,21]. The first-line antiretroviral
treatment regimen consists of two nucleoside reverse transcriptase
inhibitors (lamivudine plus zidovudine, stavudine or abacavir) and a
non-nucleoside reverse transcriptase inhibitor (efavirenz or nevirapine).
Fixed dose pediatric combinations of lamivudine and stavudine are
available, as well as TriomuneH baby and junior.
Study procedures
HIV-infected children younger than 16 years of age seeking
care at the antiretroviral treatment clinic at Macha Hospital were
eligible for enrollment into a prospective, observational cohort
study beginning in September 2007. Children were evaluated at
study visits approximately every three months, at which time a
questionnaire was administered to the guardian, the child was
examined and a blood specimen was obtained. The questionnaire
included information on demographic information, household
characteristics, medical history, HIV-related stigma and adher-
ence for children receiving treatment. Adherence was measured at
each visit by pill count for children receiving pills and by weight
for children receiving syrups. Blood specimens were collected in
EDTA tubes. As part of routine clinical care, CD4
+ T cell counts
and percentages were measured using the Guava Easy CD4
system (Guava Technologies, Inc., Hayward, CA). As part of study
procedures, plasma levels of HIV RNA were quantified by a
reverse transcriptase polymerase chain reaction assay (Amplicor
HIV-1 Monitor v. 1.5, Roche Molecular Systems; lower limit of
detection: 400 copies/mL). Viral load testing was only performed
for children who started ART after study enrollment and was
performed on batched samples; therefore, results were not
available for clinical care. Information prior to study enrollment
was abstracted from medical records. Home visits were attempted
for children who missed study visits. For children who died, the
location and cause of death were ascertained through verbal
autopsy or through hospital or clinic records.
Statistical analysis
For the present analysis, all children enrolled in the study and
receiving ART between September 2007 and September 2010 were
included. This study sample consisted of two groups of children: 1)
children receiving ART at study enrollment (Group A); and 2)
children who were treatment-naı ¨ve at study enrollment and initiated
ART during the specified period (Group B). Children were included
in the analysis until they died, were lost to follow-up or were
administratively censored at September 1, 2010 or 24 months of
ART. Children whose last study visit occurred more than 6 months
prior to September 1, 2010 were considered lost to follow-up.
Data wereentered induplicateusingEpiInfo (Centers for Disease
Control and Prevention) and analyses were conducted in SAS for
Windows version 9.1 (SAS Institute Inc., Cary, NC) and STATA,
version 9 (StataCorp LP, College Station, Texas). Characteristics at
study enrollment and ART initiation were compared between
groups of children. The Wilcoxon rank sum test was used to
compare continuous variables and the chi-square test was used to
compare categorical variables. A measure of socio-economic status
(SES) was calculated based on the Demographic and Health Survey
SES scale used in Zambia [22]. SES percentiles were based on the
predetermined cutoffs (,25
th=0–6; 26–50
th=7–12; 51–75
th=13–
18; .75
th=19–24). Weight-for-age z-scores were calculated based
on the WHO growth standards [23] and children with z-scores
below 22 were defined as underweight. Severe immunodeficiency
was defined by age according to the 2006 WHO treatment
guidelines [20], and severe anemia was defined as hemoglobin
concentration ,8 g/dL [24]. If laboratory tests were not available
from the visit at which ARTwas initiated, results were used within 3
months prior to the date of initiation.
Risk factors for mortality after ART initiation were evaluated
using Cox proportional hazards models. Time since ART
initiation was used as the time axis, and late entries were used
for children in Group A. Risk factors at ART initiation of interest
included age, sex, orphan status, travel time to the clinic, CD4+ T-
cell percentage, WAZ, anemia and viral load. Factors associated
with mortality (p,0.10) in the univariable models were eligible for
inclusion in the multivariable model.
Immunologic and virologic treatment outcomes as well as
adherence were assessed. For all outcomes, children were included
if they had at least one post-ART measure available. To report
outcomes at specific time points, measurements were aggregated
to within 45 days. Immunologic treatment outcomes were
evaluated using linear mixed effects models with random intercept,
exchangeable correlation structure and robust standard error
estimation. A spline term was added at 7.5 months, the upper
window around the 6-month measure. Adherence was calculated
for each drug returned and is reported as the percentage of
medication returned of the expected use since the prior visit. For
children taking more than one drug, the minimum adherence of
all drugs was calculated. Adherence measures were capped at
100%. Both continuous and categorical measures of adherence are
reported. For the categorical measure, a child was defined as
adherent if they took more than 95% of the prescribed doses.
Predictors of viral suppression between 6 and 24 months after
ART initiation were assessed among children in group B. As
children could contribute more than one measure of viral load,
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generalized estimating equations. Predictors of interest included
age, sex, orphan status, education of the primary caregiver, socio-
economic status, travel time, ART regimen, underweight and
severe immunodeficiency at ART initiation. Adherence and the
presence of others in the household receiving ART were also
assessed at the time of each viral load measure. As the sample size
was small, separate multivariable models were built for each
predictor found to be associated with viral suppression (p,0.10) in
the univariable models. Only factors associated with the predictor
of interest were included in each multivariable model.
Results
Characteristics of the study population at study
enrollment and ART initiation
Between September 2007 and September 2010, 267 children
received ART, including 69 children who entered the study
already receiving ART (Group A) and 198 children who initiated
ART after study enrollment (Group B). Children in Group A
entered the study a median of 8.0 months (IQR: 2.3, 12.9) after
initiating ART, while children in Group B initiated ART a median
of 1.7 months (IQR: 0.9, 5.0) after study enrollment. The median
follow-up time in the study was 14.9 months (IQR: 5.0, 19.2) for
children in Group A and 11.8 months (IQR: 4.4, 20.7) for children
in Group B. The median age of children at enrollment into the
ART clinic was 2.76 years (interquartile range [IQR]: 1.42, 7.67)
among children in Group A and 2.03 years (IQR: 1.11, 4.95)
among children in Group B (p=0.07). The median age of children
at study enrollment was 3.80 years (IQR: 2.26, 8.54) among
children in Group A and 2.21 (IQR: 1.27, 5.36) in Group B, and
49.1% were male (Table 1). At ART initiation, the median age
was 2.90 years (IQR: 1.71, 7.75) in Group A and 2.69 (IQR: 1.50,
5.92) in Group B. The proportion of children who were
underweight at ART initiation was 66.7% and 53.4% among
children in Group A and B, respectively. The proportion of
children with severe immunodeficiency was 73.7% and 60.9%
among children in Group A and B, respectively.
Few mothers reported receiving antiretroviral drugs to prevent
mother-to-child transmission (5.3%). Children were primarily
Table 1. Characteristics at study enrollment and ART initiation of HIV-infected children receiving antiretroviral therapy.
Total (n=267) Group A (n=69) Group B (n=198) p-value
Study enrollment
Median age in years (IQR) 2.67 (1.41, 6.38) 3.80 (2.26, 8.54) 2.21 (1.27, 5.26) 0.001
,2 yrs 104 (39.0) 14 (20.3) 90 (45.5)
2–4.9 yrs 86 (32.2) 29 (42.0) 57 (28.8)
$5 yrs 77 (28.8) 26 (37.7) 51 (25.8) 0.001
Male sex (%) 131 (49.1) 41 (59.4) 90 (45.5) 0.05
Mother received PMTCT (%) 14 (5.3) 1 (1.5) 13 (6.6) 0.19
Vital status of parents (%)
Both alive 189 (72.1) 41 (62.1) 148 (75.5)
One parent died 52 (19.9) 15 (22.7) 37 (18.9)
Both died 21 (8.0) 10 (15.2) 11 (5.6) 0.03
Travel time (hours)(%)
,1 24 (9.1) 6 (9.1) 18 (9.1)
1–2 80 (30.4) 21 (31.8) 59 (30.0)
3–4 88 (33.5) 19 (28.8) 69 (35.0)
$5 71 (27.0) 20 (30.3) 51 (25.9) 0.80
ART initiation
Median age in years (IQR) 2.73 (1.57, 6.73) 2.90 (1.71, 7.75) 2.69 (1.50, 5.92) 0.37
,1 yr 39 (14.6) 10 (14.5) 29 (14.7)
1–1.9 yrs 59 (22.1) 12 (17.4) 47 (23.7)
2–4.9 yrs 87 (32.6) 23 (33.3) 64 (32.3)
$5 yrs 82 (30.7) 24 (34.8) 58 (29.3) 0.69
Median WAZ (IQR)
b 22.28 (23.37, 21.39) 22.48 (23.64, 21.72) 22.16 (23.22, 21.34) 0.10
Underweight (%) 120 (56.6) 34 (66.7) 86 (53.4) 0.10
Missing (%) 55 (20.6) 18 (26.1) 37 (18.7)
Median CD4% (IQR) 15.9 (10.5, 20.1) 13.1 (9.4, 16.2) 16.8 (10.9, 20.6) 0.03
Severe immunodeficiency (%)
b 140 (63.1) 28 (73.7) 112 (60.9) 0.14
Missing (%) 45 (16.9) 31 (44.9) 14 (7.1)
Group A: children who entered the study already receiving ART; Group B: children who initiated ART after study enrollment.
aAmong respondents who were primary caregivers (n=247).
bAmong children ,10 years of age.
cDefined by age according to the 2006 WHO guidelines.
doi:10.1371/journal.pone.0019006.t001
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least one parent had died. Other primary caregivers included
grandparents (11.7%) and aunts or uncles (7.2%). The education
level of the primary caregiver was low, with 5.7% reporting no
education and 58.5% reporting no more than a primary school
education, 52.1% of whom completed grade 7. Only 35%
reported a secondary school education. In addition, 80.9% of
caregivers reported being able to read either Tonga or English.
The majority (65.8%) of children lived in households with a SES in
the lowest quartile and 30% lived in households with a SES in the
second lowest quartile. Children who initiated ART prior to study
enrollment were more likely to be male, to have lost both parents,
and to have initiated ART with a lower median CD4
+ T-cell
percentage (Table 1).
Mortality
Within the first two years after ART initiation, 27 children
(10.1%) died (Group A: 5 (7.3%); Group B: 22 (11.1%); p=0.36),
13 children (4.9%) transferred to another clinic (Group A: 2
(2.9%); Group B: 11 (5.6%); p=0.38), and 4 children (1.5%)
defaulted (Group A: 1 (1.5%); Group B: 3 (1.5%); p=0.97). The
proportion of children who defaulted among those enrolled for
more than 6 months prior to September 1, 2010 was 1.7%.
The majority of deaths occurred within the first few months of
starting ART. Among children initiating ART after study
enrollment (Group B), the median time to death from ART
initiation was 3.08 months (IQR: 0.59, 6.33). Among all children,
the cumulative probabilities of death were 9.0% (95% CI: 5.8,
13.9), 12.0% (95% CI: 8.1, 17.5) and 14.4% (95% CI: 9.9, 20.6) at
6, 12, and 24 months after ART initiation, respectively.
Information on cause of death was available for 18 children.
Contributing factors included diarrhea (n=9), malnutrition
(n=8), tuberculosis (n=5), pneumonia (n=5), meningitis (n=2),
cerebral malaria (n=1), encephalopathy (n=1), and possible
Kaposi’s sarcoma (n=1). Location of death was available for 21
children. Ten children died in the hospital (47.6%), two children
died on the way to the hospital (9.5%), one child died in the rural
health center (4.8%), and eight children died at home (38.1%).
Younger age, lower WAZ, lower CD4+ T-cell percentage and
high viral load (.750,000 copies/mL) at ART initiation were
associated with a higher risk of mortality (Table 2). Only younger
age and lower WAZ remained significantly associated with higher
mortality after adjusting for other factors.
Immunologic and virologic treatment outcomes
Among children with at least one post-ART measure,
immunologic and virologic treatment outcomes improved within
three to six months of starting ART (Table 3). Mean CD4
+ T-cell
percentage increased from 16.3% at treatment initiation to 29.3%,
33.9%, 33.0% and 35.0% at 6, 12, 18 and 24 months on ART.
Consequently, the proportion of children with a CD4
+ T-cell
percentage .25% increased from 10.9% at treatment initiation to
66.7%, 81.5%, 84.5% and 87.5% at 6, 12, 18, and 24 months
on ART. Results of the longitudinal models indicated that
CD4
+ T-cell percentage increased by 1.80 (standard error [SE]:
0.088; p-value=,0.0001) percentage points per month in the
first 6 months, and then increased by 0.23 (SE: 0.058;
p-value=,0.0001) percentage points per month thereafter. No
difference in the pattern of improvement was found by age, sex or
underweight status at ART initiation. Monthly increases in CD4
+
T-cell percentages in children with severe immunodeficiency at
ART initiation were significantly greater than in children without
severe immunodeficiency, both within the first 6 months (2.04
[SE: 0.11], p-value=,0.0001 vs. 1.60 per month [SE: 0.15],
p-value=,0.0001; p-interaction=0.02) and after 6 months of
ART (0.30 [SE: 0.09], p-value=0.001 vs. 0.075 [SE: 0.07],
p-value=0.28; p-interaction=0.04) (Figure 1).
Median viral load decreased rapidly after the start of ART, from
5.4 log copies/mL at treatment initiation to ,2.6 log copies/mL
throughout treatment (Table 2). The proportion of children with
undetectable viral load increased to 90.0%, 88.5%, 88.3%, 86.8%
and 77.8% at 3, 6, 12, 18 and 24 months on ART. One hundred
and four children received ART for at least 6 months, 90 (87%) of
whom had persistent undetectable viral loads at or beyond 6
months of ART. Fourteen children (13%) had at least one sample
with detectable viral load, of whom 4 (29%) had persistent
detectable viral load, 3 (21%) had detectable viral load at more
than one visit, 6 (43%) had viral rebound which then remained
undetectable, and 1 (7%) had a detectable viral load on their last
available sample.
The 4 children with persistent detectable viral load had no
evidence of clinical or immunologic failure, and no children in
group B were switched to a second line regimen due to treatment
failure during the study period. One child in group A was switched
to a second line regimen including a protease inhibitor due to
clinical and immunologic failure 20.7months after initiation.
Adherence
Adherence data were available for at least one study visit for 216
children (Group A: 55; Group B: 161). Estimated adherence,
defined as the minimum adherence of all drugs taken, over the
study period was high, with a median of 98–100% at all time
Table 2. Risk factors for mortality after initiation of
antiretroviral treatment.
Characteristics at
ART initiation
Crude hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
Female 1.03 (0.48, 2.20)
Age 0.79 (0.66, 0.95) 0.40 (0.22, 0.74)
,1 yr 8.72 (1.79, 42.47)
1–1.9 yrs 9.81 (2.21, 43.66)
2–4.9 yrs 2.44 (0.47, 12.58)
$5 yrs 1
Orphan 0.68 (0.26, 1.79)
Travel time
,1h r 1
1–2 hrs 2.91 (0.37, 22.96)
3–4 hrs 2.22 (0.28, 17.57)
$5 hrs 2.93 (0.37, 23.48)
WAZ
a 0.55 (0.43, 0.72) 0.64 (0.48, 0.86)
$221
22.1 to 23 3.68 (0.67, 20.13)
,23 10.96 (2.49, 48.25)
Hemoglobin ,8 g/dL 1.97 (0.66, 5.91)
CD4 percentage (per 5 points) 0.77 (0.56, 1.05) 0.67 (0.44, 1.02)
Severe immunodeficiency
b 1.23 (0.49, 3.08)
Viral load .750,000 copies/mL
c 19.35 (2.31, 161.90) 3.03 (0.32, 28.58)
aAmong children ,10 years of age.
bDefined by age according to the 2006 WHO guidelines.
cAn indicator for missing viral load was included in the multivariable model as
viral load at ART initiation was only available on a subset of children.
doi:10.1371/journal.pone.0019006.t002
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proportion of children who were non-adherent (adherence
percentage less than 95%) decreased over time, from 35.3% at 3
months to 25.4% at 24 months. We examined patterns of
adherence over time to determine if the same children were
consistently non-adherent. Among the 172 children who had at
least 2 adherence measures at study visits, 74 (43%) were
consistently adherent, 3 (2%) were consistently non-adherent,
Table 3. Immunologic and virologic outcomes and adherence by time on treatment.
Treatment initiation 3 months 6 months 12 months 18 months 24 months
Immunologic outcome N=183 N=149 N=135 N=119 N=97 N=72
Mean CD4% (STD) 16.3 (7.6) 26.6 (11.0) 29.3 (10.4) 33.9 (9.6) 33.0 (9.0) 35.0 (8.5)
Mean change in CD4% from ART initiation (STD) — 9.4 (8.9) 12.4 (8.5) 17.4 (8.8) 17.3 (9.9) 19.0 (9.2)
% with CD4%.25% 10.9 54.4 66.7 81.5 84.5 87.5
% missing, of those in care
a 7.8 27.7 25.0 23.7 20.5 20.0
Virologic outcome
b N=106 N=100 N=96 N=77 N=53 N=27
Median log VL (IQR) 5.4 (5.0, 5.9) 2.6 (2.6, 2.6) 2.6 (2.6, 2.6) 2.6 (2.6, 2.6) 2.6 (2.6, 2.6) 2.6 (2.6, 2.6)
Median change in log
VL from ART initiation (IQR)
— 22.7
(23.3, 22.2)
22.7
(23.3, 22.1)
22.6
(23.3, 21.8)
22.6
(22.8, 21.8)
22.4
(22.7, 21.1)
% with undetectable VL — 90.0 88.5 88.3 86.8 77.8
% missing, of those in care
a 46.5 45.1 35.1 29.4 30.3 34.1
Adherence N=150 N=133 N=115 N=87 N=71
Median (IQR) — 98.5 (89, 100) 98 (93, 100) 99 (96, 100) 100 (96, 100) 99 (95, 100)
% #95% — 35.3 32.3 23.5 24.1 25.4
% missing, of those in care
a 27.2 26.1 26.3 28.7 21.1
Note: Immunologic and virologic treatment outcomes were evaluated among children with at least one post-ART measure available.
aChildren in care were defined as those who were enrolled in the study and presented to the clinic at the specified visit or, if the visit was missed, at any subsequent
visit.
bThe analysis was restricted to children in group B for the virologic outcome.
doi:10.1371/journal.pone.0019006.t003
Figure 1. Mean CD4+ T-cell percentage (95% CI) after ART initiation, by level of immunodeficiency at initiation.
doi:10.1371/journal.pone.0019006.g001
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non-adherence. Adherence was not associated with any charac-
teristics of the child or caregivers. Children taking ART regimens
including fixed dose combinations were, however, less likely to be
non-adherent (e.g. 45.2% of children taking individual drugs were
non-adherent compared to 7.1% of children taking fixed dose
combinations 9 months after ART initiation; p=0.01). Non-
adherence was also marginally associated with a lower risk of
achieving viral suppression (odds ratio: 0.68; 95% CI: 0.46, 1.01;
p=0.05).
Predictors of viral suppression after 6 months of ART
Longer travel time, younger age, non-orphan status and use of
nevirapine at ART initiation were significantly associated with a
lower risk of viral suppression (Table 4; Figure 2). These
characteristics were correlated, as children with shorter travel
times were more likely to be older and to be orphans. Children
receiving nevirapine were also more likely to be younger. After
adjustment, longer travel times and use of nevirapine remained
marginally associated with a lower risk of viral suppression.
Discussion
This study of treatment outcomes among HIV-infected children in
Zambia demonstrated that ART could effectively be delivered in this
rural setting and that these children responded well to treatment.
Two groups of children were assessed, those who entered the study
receiving ART and those who initiated ART during the study period.
Children in the latter group were younger and had better clinical and
immunological profiles. While the children receiving ART at study
entry represented a subset of children who initiated ART at the clinic
prior to the start of this study, these findings are consistent with a
previous study in this population demonstrating improvements in the
enrollment and treatment of children at younger ages and less severe
stages of disease progression [25].
Theproportionofchildrenwhodied(14.4%)within24monthsof
starting ART was higher than reported from other studies of
children in sub-Saharan Africa. The KIDS-ART-LINC study in 17
sites across sub-Saharan Africa reported cumulative probabilities of
mortality of 4.8%, 6.0% and 6.0% at 6, 12 and 24 months [26],
respectively, while the International epidemiologic Databases to
Evaluate AIDS in Southern Africa (IeDEA-SA) study across 10 sites
in southern Africa reported probabilities of 4.5% and 7.7% at 12
and 36 months [27,28], respectively. This difference may partially
be explained by the relatively younger and more undernourished
rural population in this study, as both of these factors are associated
with higher mortality [2]. However, the difference may also be
explained by the lower observed loss to follow-up of 1.5% at 24
months in this study, compared to 10.3% in the KIDS-ART-LINC
study over the same time period [26]. Among adults, approximately
40% of losses to follow-up represented unreported deaths [29]. In
fact, when the IeDEA-SA study accounted for mortality among
losses to follow-up, the 12 month mortality increased from 4.5% to
8.7% [28]. Consequently, the high mortality and low loss to follow-
upinthisstudycouldalso beduetomore completeascertainment of
outcomes as a result of contact tracing. The majority of deaths
occurred within the first 3 months of ART and were associated with
youngerage,lowerWAZ,lowerCD4
+T-cell percentage and higher
viral load, consistent with other observations [2].
Children followed in this study achieved good immunologic and
virologic treatment outcomes, such that 88% had a CD4
+ T-cell
percentage greater than 25% and 78% had an undetectable HIV
viral load 24 months after initiating ART. Contrary to the results
of an earlier cross-sectional analysis in this cohort [5], early gains
in CD4
+ T-cell percentages were maintained throughout follow-
up. Similar improvements in immune status were observed in
other African studies [2]. The level of viral suppression in this
cohort, however, was higher than reported in many other studies
of African children [2,27]. Few studies are available for
comparison from rural areas, but one study in rural South Africa
reported that 71% of children remaining on treatment after 12
months achieved viral suppression [30].
Correlates of viral suppression were explored, including
established factors such as drug regimen and adherence, and
factors related to treatment in a rural setting, such as travel time to
the clinic. Clinical trials in adults [31,32] and observational studies
in children [33,34,35] showed higher rates of virologic failure with
nevirapine-based regimens compared to efavirenz-based regimens,
Table 4. Predictors of viral suppression after 6 months of
antiretroviral therapy.
Crude odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
Characteristics at ART initiation
Female 0.69 (0.25, 1.94)
Age
,1 yr 0.32 (0.05, 2.07) 1.01 (0.05, 2.82)
1–1.9 yrs 0.16 (0.03, 0.84) 0.85 (0.14, 4.95)
2–4.9 yrs 0.39 (0.07, 1.98) 1.08 (0.10,
11.35)
d
$5 yrs 1 1
Orphan 7.22 (1.61, 32.45) 3.32 (0.64, 17.30)
e
Travel time
,1h r 1 1
1–2 hrs 0.34 (0.04, 3.16) 0.51 (0.07, 3.86)
3–4 hrs 0.20 (0.03, 1.65) 0.36 (0.05, 2.37)
$5 hrs 0.10 (0.01, 0.82) 0.17 (0.02, 1.19)
e
High SES (.50
th percentile) 2.28 (0.35, 15.00)
Education of the primary caregiver
None/Primary school 1
Secondary school/university 1.22 (0.40, 3.78)
Underweight
a 0.87 (0.28, 2.68)
Severe immunodeficiency
b 0.70 (0.24, 2.03)
High viral load
(.750,000 copies/mL)
c
0.60 (0.17, 2.04)
ART regimen including stavudine 0.47 (0.15, 1.48)
ART regimen including nevirapine 0.35 (0.46, 0.98) 0.33 (0.11, 1.03)
f
ART regimen including fixed dose
combinations
2.30 (0.65, 8.10)
Characteristics at each
viral load measure
Other people in the
household on ART
0.78 (0.48, 1.27)
aAmong children ,10 years of age.
bDefined by age according to the 2006 WHO guidelines.
cAn indicator for missing viral load was included in the multivariable model as
viral load at ART initiation was only available on a subset of children.
dMultivariable model included orphan status, travel time, nevirapine and age at
ART initiation.
eMultivariable model included orphan status, travel time and age at ART
initiation.
fMultivariable model included age and nevirapine at ART initiation.
doi:10.1371/journal.pone.0019006.t004
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throughout treatment and was associated with viral suppression.
However, despite being one of the main determinants of viral
suppression after ART initiation, adherence has not consistently
been found to correlate with viral suppression in children
[36,37,38], perhaps due to the difficulties in measuring adherence
among children, including complex drug regimens, use of pills and
syrups, and the potential involvement of multiple caregivers in the
administering of medication [39]. This study attempted to
overcome these difficulties by using a more objective measure of
adherence by medication returns rather than self-report.
The main novel factor associated with viral suppression was
travel time. As this was a rural population, participants travelled
from surrounding villages to the clinic and over a quarter of the
study population reported travelling five or more hours.
Transportation and distance have been reported as barriers to
care and treatment in this [5] and other adult and pediatric
populations [6,7,8,40], as long travel distances or times incur a
direct cost for transportation and indirect cost for time away from
work and childcare. Distance to the clinic was associated with
retention in this clinic, with children living farther away from the
clinic more likely to be lost to follow-up [9]. However, this is the
first report of an association between travel time and virologic
outcome, with children travelling five or more hours significantly
less likely to achieve viral suppression. This relationship is
hypothesized to be due to the impact of travel time on the
frequency of visits to the clinic and pharmacy. In this study,
associations between travel time and missed or delayed visits as
well as adherence were not found; however, information on
pharmacy or clinic appointments in between study visits was not
available. This finding should be confirmed in other populations as
it has important implications for the treatment of HIV-infected
children as treatment programs are increasingly implemented and
scaled up in rural areas.
The main limitations of the study include the small sample
size, particularly at longer follow-up times, and missing data on
adherence and treatment outcomes, which may have led to an
overestimation of the success of ART. However, this is one of
the few pediatric studies conducted in rural sub-Saharan Africa,
and the high proportion of children with available immunologic
and virologic measures suggests minimal bias for these outcomes.
In addition, children cared for at the Macha ART clinic benefit
from being enrolled in a research study and attending a faith-
based health facility, which may have higher levels of support
and staffing than government clinics in the same region. While
the study relied on laboratory tests (with the exception of viral
load) and clinical measures performed as part of routine care to
minimize this bias, the good treatment outcomes observed in this
study may not be generalizable to other rural government
clinics.
In summary, this study demonstrated that ART can effectively
be delivered in a rural setting and that children experienced
sustainable immunologic and virologic improvements after
initiating ART. The observed detrimental effect of long travel
times on virologic suppression may have implications for ART
delivery in this setting. As treatment programs expand further into
rural areas, clinic catchment areas will expand. Unless decentral-
ized models of care are implemented, children may have to travel
great distances for their care and treatment, which may impact
both their ability to remain in care and respond to treatment.
Figure 2. Percentage of children achieving viral suppression after 6 months of ART, by travel time.
doi:10.1371/journal.pone.0019006.g002
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